 |
인쇄하기
취소
|
Local phase III study of Xeloda confirmed stomach cancer therapy.
A multinational clinical study was completed by a Korean researcher for the first time in Korea and presented at an international conference.
Roche Korea announced on June 7 that Prof. Kang Yun-goo of the oncology department of Seoul Asan hospital, the chief clinical researcher in a large scale of the multinational clinical study project for Xeloda (capecitabine), an oral anti-cancer drug, p...
Roche Korea announced on June 7 that Prof. Kang Yun-goo of the oncology department of Seoul Asan hospital, the chief clinical researcher in a large scale of the multinational clinical study project for Xeloda (capecitabine), an oral anti-cancer drug, p...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.